Weal and flare responses to intradermal rocuronium and cisatracurium in humans

84Citations
Citations of this article
14Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Thirty volunteers underwent intradermal skin testing with increasing concentrations of rocuronium and cisatracurium to evaluate weal and flare responses, and whether either agent would cause mast cell degranulation and sensitization upon re-exposure. We found that intradermal injection of rocuronium and cisatracurium at concentrations > 10-4 M resulted in positive weal (>8 mm) responses, and positive flare responses at >10-4 and >10-5 M respectively. Only cisatracurium caused mild to moderate mast cell degranulation, and neither drug caused significant in vitro histamine release from whole blood collected from study subjects 4 weeks after skin testing. Skin testing with rocuronium and cisatracurium should be performed at concentrations <10-4 and <10-5 M respectively to avoid false-positive responses. The ability of these agents to produce positive weal and flare responses at relatively low concentrations may explain the high incidence of potential reactions reported.

Cite

CITATION STYLE

APA

Levy, J. H., Gottge, M., Szlam, F., Zaffer, R., & McCall, C. (2000). Weal and flare responses to intradermal rocuronium and cisatracurium in humans. British Journal of Anaesthesia, 85(6), 844–849. https://doi.org/10.1093/bja/85.6.844

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free